NCT05136456: Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous Nephropathy |
|
|
| Active, not recruiting | 2 | 61 | RoW | SHR1459 Low Dose, SHR1459 High Dose, Placebo | Reistone Biopharma Company Limited | Primary Membranous Nephropathy | 08/23 | 03/24 | | |